BRPI0717416A2 - Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo - Google Patents

Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo

Info

Publication number
BRPI0717416A2
BRPI0717416A2 BRPI0717416-0A2A BRPI0717416A BRPI0717416A2 BR PI0717416 A2 BRPI0717416 A2 BR PI0717416A2 BR PI0717416 A BRPI0717416 A BR PI0717416A BR PI0717416 A2 BRPI0717416 A2 BR PI0717416A2
Authority
BR
Brazil
Prior art keywords
immunoason
complex
high productivity
productivity
productivity complex
Prior art date
Application number
BRPI0717416-0A2A
Other languages
English (en)
Inventor
Jeanne Harvey
Sharat Singh
Phillip Kim
Xinjun Liu
Robert Barham
Limin Liu
Original Assignee
Prometheus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Lab Inc filed Critical Prometheus Lab Inc
Priority claimed from PCT/US2007/079002 external-priority patent/WO2008036802A2/en
Publication of BRPI0717416A2 publication Critical patent/BRPI0717416A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/08—Methods of screening libraries by measuring catalytic activity
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
BRPI0717416-0A2A 2006-09-21 2007-09-20 Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo BRPI0717416A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US752706P 2006-09-21 2006-09-21
US91308707P 2007-04-20 2007-04-20
PCT/US2007/079002 WO2008036802A2 (en) 2006-09-21 2007-09-20 Antibody-based arrays for detecting multiple signal transducers in rare circulating cells

Publications (1)

Publication Number Publication Date
BRPI0717416A2 true BRPI0717416A2 (pt) 2013-11-12

Family

ID=49549722

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717416-0A2A BRPI0717416A2 (pt) 2006-09-21 2007-09-20 Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo

Country Status (2)

Country Link
US (4) US8658388B2 (pt)
BR (1) BRPI0717416A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
NZ582618A (en) * 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
JP5264421B2 (ja) * 2007-11-22 2013-08-14 富士フイルム株式会社 被験物測定用担体およびその製造方法
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
KR20100042082A (ko) * 2008-10-15 2010-04-23 삼성전자주식회사 신호물질의 밀도가 증가되어 있는 고체 지지체, 그를 포함하는 키트 및 그를 이용한 표적물질 검출 방법
US20120178645A1 (en) * 2009-06-26 2012-07-12 Johannes Albert Foekens Identifying circulating tumor cells (ctcs) using cd146 in breast cancer patients
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
US9523701B2 (en) 2009-07-29 2016-12-20 Dynex Technologies, Inc. Sample plate systems and methods
GB0913258D0 (en) 2009-07-29 2009-09-02 Dynex Technologies Inc Reagent dispenser
DK2491385T3 (en) 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
US9034658B2 (en) 2009-11-23 2015-05-19 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
US20120252856A1 (en) * 2009-12-11 2012-10-04 Dignity Health Pi3k/akt pathway subgroups in cancer: methods of using biomarkers for diagnosis and therapy
US10731221B2 (en) 2009-12-11 2020-08-04 Dignity Health Diagnosing IDH1 related subgroups and treatment of cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP6323978B2 (ja) 2010-12-24 2018-05-16 アークレイ株式会社 癌細胞の検出方法
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
BR112013020992A2 (pt) 2011-02-17 2016-10-11 Nestec Sa aparelho e método para isolamento de leucócitos e células tumorosas por meio de filtração
KR20140020318A (ko) * 2011-04-04 2014-02-18 네스텍 소시에테아노님 위암 환자의 생존률 예측 및 개선 방법
DE102011106984B3 (de) * 2011-07-08 2012-10-11 Sartorius Stedim Biotech Gmbh Microarray-Vorrichtung für das Screenen oder Auffinden von HSP90 Inhibitoren und von Inhibitoren weiterer krankheitsrelevanter Zielstrukturen
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
EP2788752B1 (en) 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
MX355567B (es) * 2011-12-30 2018-04-23 Quest Diagnostics Invest Inc Aptameros y metodos de diagnostico para detectar el receptor de egf.
DE112013006579B4 (de) * 2013-02-02 2024-09-05 Duke University Verfahren zum Isolieren zirkulierender Tumorzellen
HK1218939A1 (zh) 2013-02-05 2017-03-17 Nestec S.A. 用於非小细胞肺癌疗法的药物选择
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
US10570648B2 (en) * 2015-12-30 2020-02-25 Inteva Products, Llc Inertia locking device for vehicle latch
WO2019028422A1 (en) 2017-08-04 2019-02-07 Trutino Biosciences METHODS OF ACTIVATION OF IMMUNE CELLS
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN109100512A (zh) * 2018-08-02 2018-12-28 宁波奥丞生物科技有限公司 一种检测egfr的化学发光试剂盒
CA3170531A1 (en) * 2020-02-11 2021-08-19 Absci Corporation Proximity assay
CN117092330A (zh) * 2023-08-10 2023-11-21 广州市雷德生物科技有限公司 一种酪胺信号放大发光检测方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
SE8500817D0 (sv) 1985-02-20 1985-02-20 Lars Jonsson Halvoppet anestesisystem
US4975532A (en) 1986-11-28 1990-12-04 Sclavo, Inc. Method to derivatize dextran
JPH01163661A (ja) 1987-10-02 1989-06-27 E I Du Pont De Nemours & Co ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ
US5192660A (en) 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US5089419A (en) 1989-08-07 1992-02-18 International Canine Genetics Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals
US5120660A (en) 1989-12-05 1992-06-09 International Canine Genetics, Inc. Method for canine fertility detection
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
JPH06109734A (ja) 1992-09-30 1994-04-22 S R L:Kk 抗原の測定方法
US6201109B1 (en) 1993-01-13 2001-03-13 Dade Behring Marburg Gmbh Assay for bone alkaline phosphatase
JP3825815B2 (ja) 1994-01-31 2006-09-27 信義 清水 上皮細胞増殖因子レセプターに対するモノクローナル抗体の結合体ならびにその複合体およびその細胞への嵌入方法
FI98961C (fi) 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5876944A (en) 1996-06-10 1999-03-02 Bayer Corporation Method for amplification of the response signal in a sandwich immunoassay
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
RU2165081C2 (ru) 1999-01-05 2001-04-10 Ставропольский научно-исследовательский противочумный институт Способ индикации микроорганизмов
US6335173B1 (en) 1999-01-12 2002-01-01 Verve, Ltd. C/O James Bell Methods for detecting an analyte of interest using tyramide coating technology
GB9901072D0 (en) 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
RU2149404C1 (ru) 1999-03-24 2000-05-20 Московский НИИ глазных болезней им. Гельмгольца Способ прогнозирования клинического течения увеальной меланомы
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6649351B2 (en) 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
DE19926010C2 (de) 1999-06-08 2003-01-30 Bundesdruckerei Gmbh Wert- und Sicherheitsdokument mit Sicherheitsmerkmal mit Piezo-Effekt-basierten Eigenschaften und dazugehöriges Nachweisverfahren
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
AU1630501A (en) 1999-10-08 2001-04-23 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
CA2385614A1 (en) 1999-10-13 2001-04-19 Timothy Johann Multiplex cytokine analysis
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US6511809B2 (en) 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
US7785810B2 (en) 2000-09-09 2010-08-31 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6797481B1 (en) 2000-10-17 2004-09-28 Dade Behring Marburg Gmbh Simultaneous screening of multiple analytes
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
DE10064827A1 (de) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Nachweisverfahren
US20070111944A1 (en) 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20020168641A1 (en) 2001-03-09 2002-11-14 Bruce Mortensen Fluorescein-cyanine 5 as a fluorescence resonance energy transfer pair
US20020142361A1 (en) 2001-03-27 2002-10-03 Emmert-Buck Michael R. Biodetection method
US20040265923A1 (en) 2001-05-03 2004-12-30 James Gilmore Method and apparatus to determine the performance of protein arrays
WO2002103321A2 (en) 2001-06-14 2002-12-27 Anadys Pharmaceuticals, Inc. Methods of screening for ligands of target molecules
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
AU2002322461B2 (en) 2001-07-12 2007-12-06 Vegenics Limited Lymphatic endothelial cells materials and methods
US8323903B2 (en) * 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US20050069962A1 (en) * 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
AU2002363530A1 (en) 2001-11-07 2003-05-19 Sensor Technologies Llc Method of identifying energy transfer sensors for analytes
EP1478765A4 (en) 2002-03-05 2006-12-06 Aclara Biosciences Inc MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
AU2003223495A1 (en) 2002-04-05 2003-10-27 Cell Signaling Technology, Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
FR2843126B1 (fr) 2002-08-01 2006-01-27 Cis Bio Int "methode de determination d'une activite enzymatique endoglycosidase"
US20040235002A1 (en) * 2002-09-20 2004-11-25 Sangamo Biosciences, Inc. Multiplex screening assays
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
US20040265938A1 (en) 2003-06-25 2004-12-30 Jose Remacle Method for the determination of cell activation
US7279286B2 (en) 2003-09-11 2007-10-09 Sanofi-Aventis Deutschland Gmbh High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity
FI20031370A0 (fi) 2003-09-23 2003-09-23 Wallac Oy Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
WO2005037071A2 (en) 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
ES2343840T3 (es) 2003-11-04 2010-08-11 Bayer Healthcare Llc Procedimientos inmunohistoquimicos para supervisar los niveles de perk.
JP2007526460A (ja) 2004-03-03 2007-09-13 バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
WO2006031815A2 (en) * 2004-09-13 2006-03-23 Monogram Biosciences, Inc. Methods and compositions for proximity assays
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2006045991A1 (en) 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
WO2006055739A2 (en) 2004-11-17 2006-05-26 Robert Sack Stationary phase antibody arrays for trace protein analysis
WO2006054991A1 (en) 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
DE102004056794B4 (de) 2004-11-24 2010-08-26 Protagen Ag Verwendung einer Anordnung und Verfahren zur Validierung von Bindern
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US8367351B2 (en) 2006-05-05 2013-02-05 Historx, Inc. Methods for determining signal transduction activity in tumors
WO2008019375A2 (en) 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
CN104198705B (zh) 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
BRPI0718413A2 (pt) 2006-10-23 2014-03-11 The Uab Research Foundation Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex
WO2008055314A1 (en) 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
WO2008064884A1 (en) 2006-11-28 2008-06-05 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
JP2008292424A (ja) 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
NZ582618A (en) 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
EP2065475A1 (en) 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
US20120270745A1 (en) 2009-07-15 2012-10-25 Prometheus Laboratories Inc. Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
US8163449B2 (en) * 2010-08-05 2012-04-24 Xerox Corporation Anti-static and slippery anti-curl back coating
WO2012047294A2 (en) 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
US20120231965A1 (en) 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20130216523A1 (en) 2011-03-31 2013-08-22 Laboratory Corporation Of America Holdings Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링

Also Published As

Publication number Publication date
US9285369B2 (en) 2016-03-15
US8658388B2 (en) 2014-02-25
US9575066B2 (en) 2017-02-21
US20150051107A1 (en) 2015-02-19
US10527622B2 (en) 2020-01-07
US20140187445A1 (en) 2014-07-03
US20170184592A1 (en) 2017-06-29
US20080261829A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
BRPI0716634A2 (pt) mÉtodo de soldagem para execuÇço de um processo de soldagem
BRPI0720235A2 (pt) Método para produzir um item de vestuário, e, item de vestuário
BRPI0817292A2 (pt) Método e aparelho para completação de poços.
BRPI0917639A2 (pt) aparelho utilizável em umpoço, e método utilizável em um poço.
BRPI0908192A2 (pt) Dispositivo funcional, e, método para produzir um dispositivo funcional
BRPI0821729A2 (pt) Tapete, revestimento de tapete e método para fabricar um tapete
BRPI0921310A2 (pt) método para fabricar um compósito, compósito, e, aparelho
BRPI0811763A2 (pt) Método para completar uma transação, meio legível por computador, servidor, e, telefone
BRPI0811764A2 (pt) Dispositivo de exibição, método de acionamento para um dispositivo de exibição, e, programa de computador
BRPI0822723A2 (pt) Método para fabricar um cartão de transação, e, cartão de transação
BRPI0811750A2 (pt) Método para produzir um inversor de enriquecimento-empobrecimento, e, inversor
BRPI0820830A2 (pt) Método para modelar em um computador para região física, e, produto de programa de computador.
BRPI0816652A2 (pt) Método para processar uma transação, meio legível por computador, instruções legíveis por máquina, e, aparelho
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0718974A2 (pt) Copolímero, e, método para preparar um copolímero
BRPI0912921A2 (pt) complexo metal-ligante, catalisador e processo para preparo de uma poliolefina
BRPI0812054A2 (pt) Processo para preparar compostos, e, compostos.
BRPI0818571A2 (pt) Cartucho para um biossensor, e, método para fabricar um cartucho
BRPI0816429A2 (pt) microorganismo, e, método para a produção de um l-aminoácido.
BRPI0902898A2 (pt) Painel de toque, e, método para produzir um painel de toque.
BRPI0718155A2 (pt) Composto, uso de um composto, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.
DE602007009134D1 (de) Vorrichtung, verfahren und computerprogramm zum erionen
BRPI0919615A2 (pt) método e dispositivo para operação de um processo de redução de fundição
BRPI1007431A2 (pt) aparelho de suporte de operação, método de suporte de operação, e programa de computador.
BRPI0907391A2 (pt) Método para a preparação de um formador de escória espumante, produto e uso do mesmo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NESTEC S.A. (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL